RDY
Dr. Reddy'S Laboratories·NYSE
--
--(--)
--
--(--)
RDY fundamentals
Dr. Reddy'S Laboratories (RDY) released its earnings on Jan 21, 2026: revenue was 951.64M (YoY -1.85%), beat estimates; EPS was 0.1583 (YoY -19.44%), missed estimates.
Revenue / YoY
951.64M
-1.85%
EPS / YoY
0.1583
-19.44%
Report date
Jan 21, 2026
RDY Earnings Call Summary for Q3,2026
- Revenue Beat Expectations: 4.4% YoY growth driven by double-digit base business growth and India's 19% YoY expansion.
- Semaglutide Momentum: India launch in March 2026, Canada approval by May 2026, with global capacity of 12 million cartridges.
- Biosimilar Pipeline Progress: Abatacept IV BLA filed, denosumab partner addressing CRL, and rituximab inspection ongoing.
- Sustainability Commitment: Science-based net-zero target by 2045, recognized for climate leadership.
- Margin Challenges: 500+ bps gross margin decline due to Lenalidomide decline, offset by 25%+ EBITDA margin in NRT business.
EPS
Actual | 0.1214 | 0.0932 | 0.1241 | 0.0033 | 0.0909 | 0.0923 | 0.1593 | 0.1132 | 0.1298 | 0.179 | 0.1622 | 0.1837 | 0.1404 | 0.2056 | 0.2133 | 0.199 | 0.1876 | 0.1993 | 0.1784 | 0.1965 | 0.2238 | 0.197 | 0.1964 | 0.1583 | ||||||||||
Forecast | 0.0875 | 0.0845 | 0.0989 | 0.116 | 0.1025 | 0.1093 | 0.1124 | 0.1274 | 0.1019 | 0.1022 | 0.1129 | 0.136 | 0.1151 | 0.154 | 0.1746 | 0.1766 | 0.1764 | 0.1923 | 0.2064 | 0.209 | 0.2115 | 0.2144 | 0.1927 | 0.1622 | ||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +38.74% | +10.30% | +25.48% | -97.16% | -11.32% | -15.55% | +41.73% | -11.15% | +27.38% | +75.15% | +43.67% | +35.07% | +21.98% | +33.51% | +22.16% | +12.68% | +6.35% | +3.64% | -13.57% | -5.98% | +5.82% | -8.12% | +1.92% | -2.40% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 584.65M | 590.57M | 662.82M | 675.66M | 645.77M | 661.38M | 769.74M | 708.93M | 699.44M | 653.93M | 764.59M | 829.77M | 767.05M | 822.36M | 826.44M | 868.04M | 848.07M | 916.27M | 951.11M | 969.62M | 996.16M | 988.91M | 1.00B | 951.64M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 561.48M | 556.17M | 640.91M | 681.07M | 656.19M | 677.83M | 696.64M | 732.85M | 678.75M | 679.18M | 695.50M | 729.14M | 745.17M | 777.84M | 816.23M | 833.41M | 847.64M | 875.74M | 918.01M | 950.54M | 978.20M | 1.01B | 979.76M | 943.77M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +4.13% | +6.19% | +3.42% | -0.79% | -1.59% | -2.43% | +10.49% | -3.26% | +3.05% | -3.72% | +9.93% | +13.80% | +2.94% | +5.72% | +1.25% | +4.15% | +0.05% | +4.63% | +3.61% | +2.01% | +1.84% | -2.56% | +2.30% | +0.83% |
Earnings Call
You can ask Aime
What factors drove the changes in Dr. Reddy'S Laboratories's revenue and profit?Did Dr. Reddy'S Laboratories beat or miss consensus estimates last quarter?What guidance did Dr. Reddy'S Laboratories's management provide for the next earnings period?What were the key takeaways from Dr. Reddy'S Laboratories's earnings call?What is the market's earnings forecast for Dr. Reddy'S Laboratories next quarter?What is the revenue and EPS growth rate for Dr. Reddy'S Laboratories year over year?What is Dr. Reddy'S Laboratories's gross profit margin?What were the key takeaways from Dr. Reddy'S Laboratories’s earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
